Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

    Technology appraisal guidance
    Discontinued

  2. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

    Technology appraisal guidance
    Discontinued

  3. Thrombophilia [ID393]

    Discontinued [GID-TAG374]

    Technology appraisal guidance
    Discontinued

  4. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  5. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  6. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

    Technology appraisal guidance
    Discontinued

  7. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    Discontinued [GID-TA11005]

    Technology appraisal guidance
    Discontinued

  10. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued [GID-TA11399]

    Technology appraisal guidance
    Discontinued

  11. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued [GID-TA11421]

    Technology appraisal guidance
    Discontinued

  12. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued [GID-TA10316]

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued [GID-TA11024]

    Technology appraisal guidance
    Discontinued

  14. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development [GID-TA10843] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE interventional procedures guidance 796.

    Interventional procedures guidance
    Published
    28 February 2018